Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Anfamon: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Anfamon - General Information

A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)

 

Pharmacology of Anfamon

Anfamon is a sympathomimetic stimulant drug marketed as an appetite suppressant. Chemically, it is the N,N-diethyl analog of cathinone. Its mechanism of action is similar to other appetite suppressants such as sibutramine, phentermine and dextroamphetamine.

 

Anfamon for patients

The patient should be cautioned about concomitant use of alcohol or other CNS-Active drugs and TENUATE or TENUATE DOSPAN.

The patient should be advised to observe caution when driving or engaging in any potentially hazardous activity.

 

Anfamon Interactions

Antidiabetic drug requirements (i.e., insulin) may be altered. Concurrent use with general anesthetics may result in arrhythmias. The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion.

 

Anfamon Contraindications

Advanced arteriosclerosis, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma, severe hypertension.

Agitated states.

Patients with a history of drug abuse.

During or within 14 days following the administration of monoamine oxidase inhibitors, hypertensive crises may result.

 

Additional information about Anfamon

Anfamon Indication: Used in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. Mechanism Of Action: Anfamon is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. Anfamon (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that diethylpropion can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage. Drug Interactions: Acetophenazine Decreased anorexic effect, may increase psychotic symptoms Chlorpromazine Decreased anorexic effect, may increase psychotic symptoms Ethopropazine Decreased anorexic effect, may increase psychotic symptoms Fluoxetine Risk of serotoninergic syndrome Fluphenazine Decreased anorexic effect, may increase psychotic symptoms Fluvoxamine Risk of serotoninergic syndrome Guanethidine The agent decreases the effect of guanethidine Isocarboxazid Possible hypertensive crisis Mesoridazine Decreased anorexic effect, may increase psychotic symptoms Methdilazine Decreased anorexic effect, may increase psychotic symptoms Paroxetine Risk of serotoninergic syndrome Perphenazine Decreased anorexic effect, may increase psychotic symptoms Phenelzine Possible hypertensive crisis Prochlorperazine Decreased anorexic effect, may increase psychotic symptoms Promazine Decreased anorexic effect, may increase psychotic symptoms Promethazine Decreased anorexic effect, may increase psychotic symptoms Propiomazine Decreased anorexic effect, may increase psychotic symptoms Rasagiline Possible hypertensive crisis Thiethylperazine Decreased anorexic effect, may increase psychotic symptoms Thioridazine Decreased anorexic effect, may increase psychotic symptoms Tranylcypromine Possible hypertensive crisis Trifluoperazine Decreased anorexic effect, may increase psychotic symptoms Triflupromazine Decreased anorexic effect, may increase psychotic symptoms Trimeprazine Decreased anorexic effect, may increase psychotic symptoms Venlafaxine Risk of serotoninergic syndrome Methotrimeprazine Decreased anorexic effect, may increase psychotic symptoms Propericiazine Decreased anorexic effect, may increase psychotic symptoms Food Interactions: Take without regard to meals. Generic Name: Diethylpropion Synonyms: Amfepramonum [INN-Latin]; Amfepramone Hydrochloride; Amfepramone HCL; alpha-Diethylaminopropiophenone; alpha-Benzoyltriethylamine; Amphepramonum hydrochloride; Anfepramona [INN-Spanish]; DEA No. 1610; Diethylcathinone; Diethylpropion HCL; Diethylpropione hydrochloride; Diethylpropione; Diethylpropion Hydrochloride Drug Category: Appetite Depressants; Anorexigenic Agents; Stimulants Drug Type: Small Molecule; Illicit; Approved Other Brand Names containing Diethylpropion: Adiposon; Amfepramon; Amfepramone; Amphepramon; Amphepramone; Anfamon; Anorex; Cegramine; Danylen; Derfon; Dobesin; Frekentine; Keramik; Keramin; Magrene; Moderatan; Modulor; Neobes; Nopropiophenone; Obesitex; Parabolin; Prefamone; Regenon; Regenon hydrochloride; Reginon; Silutin; Tenuate; Tenuate Dospan; Tenuate hydrochloride; Tepanil; Tepanil Ten-tab; Tylinal; Absorption: Diethylpropion is rapidly absorbed from the GI tract after oral administration. Toxicity (Overdose): The reported oral LD50 for mice is 600 mg/kg, for rats is 250 mg/kg and for dogs is 225 mg/kg. Manifestation of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states. Protein Binding: Not Available Biotransformation: Extensively metabolized through a complex pathway of biotransformation involving N-dealkylation and reduction. Many of these metabolites are biologically active and may participate in the therapeutic action of diethylpropion. Half Life: Using a phosphorescence assay that is specific for basic compounds containing benzoyl group, the plasma half-life of the aminoketone metabolites is estimated to be between 4 to 6 hours. Dosage Forms of Anfamon: Tablet Oral Tablet, extended release Oral Chemical IUPAC Name: 2-diethylamino-1-phenylpropan-1-one Chemical Formula: C13H19NO Diethylpropion on Wikipedia: https://en.wikipedia.org/wiki/Diethylpropion Organisms Affected: Humans and other mammals